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spirometry, BDR and FeNO testing. Where diagnostic uncertainty remained, indi-
viduals would then undergo PEF and finally MCT testing. This strategy dominated 
other strategies that did not utilise MCT, producing higher health outcomes at a 
lower cost to the health service. Two strategies that made more individuals undergo 
MCT were not cost-effective at the threshold with incremental cost-effectiveness 
ratios of £20,276 and £32,565 per/QALY respectively. Although assumptions were 
made relating to conditional dependence and the consequences of false diagnoses, 
the model’s results were found to be robust to significant changes in these and 
other uncertain parameters. ConClusions: These findings highlight the need for 
thorough objective testing for diagnosing asthma as doing so has the potential to 
improve health outcomes whilst reducing costs to the health service.
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objeCtives: The determination of coronary calcium score allows to identify indi-
viduals for which primary prevention with statins may be unnecessary. In this 
study it is shown that the presence of risk factors for developing diabetes interacts 
with the benefits of this identification. Methods: A Markov model was used to 
estimate the evolution of two cohorts with elevated C-reactive protein and low 
LDL cholesterol: one without risk factors for developing diabetes and another with 
those risk factors. The progression of both cohorts was simulated assuming four 
alternative strategies: “no treatment”, “treat if score> 100”, “treat if score> 0” and 
“treat all”. Results: For individuals without risk factors for diabetes, the “treat all” 
strategy is the most expensive but allows to achieve better clinical outcomes, with a 
cost per QALY of 24,164€ vs. the strategy “treat if score> 0”. For those with risk factors 
for diabetes, the strategy “treat all” remains the most expensive, but the decrease in 
coronary events does not compensate the increase in diabetes incidence, whereby 
the strategy “treat all” is dominated by “treat if score> 0”. The cost per QALY of this 
latter strategy in comparison to “treat if score> 100” is 36,034€ . Deterministic and 
probabilistic sensitivity analysis show that results are robust. ConClusions: The 
presence of risk factors for diabetes affects the cost-effectiveness of using coronary 
calcium score as a guide to implement primary prevention in this population.
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objeCtives: Each year approximately 900,000 new cases of hematological malig-
nancies are diagnosed globally. Diagnosis is comprised of multiple modalities, 
including flow cytometry. Current laboratory developed testing (LDT) for flow cytom-
etry is non-standardized and error prone. Insufficient research has been published 
evaluating the cost and errors in this space. Manual work, including steps such as 
antibody selection, compensation, and pipetting have been identified as potential 
sources of error in flow cytometry. The aim of this study is to quantify the time 
and associated economic impact of manual work in a flow cytometry process for 
hematological malignancies. Methods: An observational study was conducted at a 
public Canadian acute care clinical laboratory in collaboration with a lean specialist 
team for the purposes of workflow analysis. The results of this pilot were used to 
inform this extended costing analysis. Evaluation of the instrument, reagent, and 
sample preparation was performed. Total opportunities for error in the workflow 
were identified (defined as steps involving manual efforts) and manual labor time 
was then used to estimate indirect costs. Results: A total of 37 steps were involved 
in instrument set-up, 81 steps for manual reagent and sample preparation, each 
of these steps containing multiple opportunities for error. At a 550 bed institution 
performing 591 leukemia and lymphoma tests annually, it was estimated that a 
total of 365 hours of manual labor by a skilled medical lab technologist incurred 
indirect costs of $18,250. ConClusions: Based on this case study, manual work 
resulted in substantial cost to the laboratory in indirect costs. This suggests that 
in addition to reducing the potential for error, minimizing unnecessary manual 
steps in the flow cytometry workflow could also reduce laboratory indirect costs 
and improve efficiency. Future research is warranted to quantify the frequency of 
errors in manual steps in LDT for flow cytometry.
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objeCtives: Human epidermal growth factor receptor 2 (HER2) status identifi-
cation is established by immunohistochemistry and in situ hybridisation (ISH). 
Silver in situ hybridisation (SISH) is an alternative technique to the fluorescence in 
situ hybridization (FISH). Both methods are recommended by American Society of 
Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2013 guidelines. 
The primary aim of this analysis is to evaluate the economical and organizational 
impact by adopting FISH or SISH test for HER2 testing. Methods: We conducted 
an analysis to evaluate costs, times (laboratory personnel working hours) and 
laboratory-space to process a sample using the manual method (FISH) compared 
to the automated system (SISH). The analysis was performed from the pathology 
laboratory’s perspective. We analysed the complete workflow (laboratory personnel 
and medical resource used) to perform the two tests (FISH and SISH) during pathol-
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objeCtives: The majority of patients who get an implantable cardioverter defi-
brillator (ICD) for primary prevention of sudden cardiac death (SCD) never need to 
receive appropriate ICD therapies. Better risk-stratifying tools are thus needed to 
improve the cost-effectiveness of device implantation. The purpose of this study 
was to assess the cost-effectiveness of using delayed enhancement cardiac mag-
netic resonance (CMR) to refine patient selection for ICD therapy in primary pre-
vention. Methods: A Markov model was developed to assess long-term survival, 
quality-adjusted life years (QALYs), and lifetime costs for a cohort of patients with 
reduced left ventricular ejection fraction without previous ventricular arrhythmias. 
Two different strategies were compared: A) implant an ICD in all patients (“ICD for 
all”); and B) perform CMR and implant an ICD only in patients with delayed enhance-
ment exceeding 5% of myocardial mass (“CMR-guided ICD”). Clinical and economic 
inputs were derived from European representative literature. Results: The “ICD 
for all” strategy led to a total cost of 68,818€ and 7.0 QALY per patient, implying an 
incremental cost of 7,372€ and allowing a gain of 0.1 QALY when compared to the 
strategy “CMR-guided ICD”. Consequently, the cost-utility ratio is 77,943€ per QALY. 
Probabilistic sensitivity analysis showed that, assuming a willingness to pay of 
50,000€ per QALY, the “ICD for all” strategy would be cost-effective in 31 % of the sim-
ulations. ConClusions: Results suggest that implanting ICD in selected patients 
allows to use this device in those that benefit most, improving the cost-effectiveness 
of ICD implantation for the primary prevention of sudden cardiac death.
PMD95
cost-eFFectiveness analysis oF testing FoR bRca1 anD bRca2 
MUtations in WoMen DiagnoseD With ovaRian canceR anD theiR 
FeMale FiRst- anD seconD DegRee Relatives Using a DiscRete event 
siMUlation: a Uk health seRvice PeRsPective
Eccleston A1, Bentley A1, Dyer M2, Vereecken W2, George A3, Rahman N3
1Abacus International, Bicester, UK, 2AstraZeneca UK Ltd., Luton, UK, 3Institute of Cancer 
Research, London, UK
objeCtives: Mutations in BRCA1 and BRCA2 genes are associated with an increased 
risk of breast and ovarian cancer. If a BRCA mutation is detected in women with 
ovarian cancer their unaffected relatives may be offered genetic testing and pro-
phylactic surgery. The long-term cost-effectiveness of providing BRCA testing to 
women with ovarian cancer and to their unaffected female first-degree relatives 
in the UK has previously been evaluated using a lifetime Markov model, but the 
approach had a number of limitations. The current study will employ a hybrid dis-
crete event simulation (DES) structure that addresses some of the Markovian limi-
tations associated with the previous model and will differentiate between BRCA1 
and BRCA2 mutations and will consider results for a number of possible UK family 
pedigrees. Methods: A hybrid DES will be constructed with a lifetime horizon, 
to evaluate the cost-effectiveness of BRCA testing in women with ovarian cancer 
and their female first- and second-degree relatives versus no testing. The model 
will consider the incidence of ovarian and breast cancer, differentiating between 
those with BRCA1 and BRCA2 mutations, as well as the associated mortality rates. 
Individuals identified as BRCA1 or BRCA2 positive will be eligible to undergo bilat-
eral mastectomy and bilateral salpingo-oophorectomy, which significantly reduce 
the risk of both ovarian and breast cancer. Results: Results will be presented as 
an incremental cost-effectiveness ratio expressed as a cost per quality adjusted 
life year (QALY). These will be compared to the UK cost-effectiveness threshold of 
£20,000 per QALY gained. A number of sensitivity and subgroup analyses will be 
presented alongside the base case. ConClusions: We aim to demonstrate that 
screening patients with ovarian cancer and their first- and second-degree relatives 
for the BRCA1 and BRCA2 mutation is cost-effective and reduces the incidence of 
breast and ovarian cancer in the population.
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objeCtives: To develop an economic model to inform recommendations on the 
optimal diagnostic pathway for the recent clinical guideline on the diagnosis and 
monitoring of asthma, commissioned by the National Institute for Health and Care 
Excellence (NICE). Methods: A de-novo economic model evaluated current prac-
tice alongside six diagnostic pathways comprising of the following tests: spirometry, 
bronchodilator reversibility (BDR), peak expiratory flow (PEF), fractional exhaled 
nitric oxide (FeNO) and methacholine/histamine challenge testing (MCT). A model 
was developed using a decision tree to identify what proportion of individuals would 
receive a correct (true positive, true negative) or incorrect (false positive, false nega-
tive) diagnosis, utilising diagnostic accuracy data in adults from systematic reviews 
conducted for each test. These proportions fed into one of four Markov models, 
depending on the diagnosis, which calculated final health and cost outcomes. The 
model explored the impact of alternative false diagnoses, such as chronic obstruc-
tive pulmonary disease, and applied modelling techniques to account for the effect 
of conditional dependence on diagnostic accuracies. Results: The most cost-effec-
tive strategy at a £20,000 per/QALY threshold consisted of all individuals undergoing 
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objeCtives: Asthma is a chronic respiratory disease with a high burden of disease 
and a relevant Public Health problem. The active patient active involvement is cru-
cial to yield the proper disease control. The aim of the study was to assess treatment 
adherence with the combination of inhaled corticosteroids (ICS) and long-acting 
beta-2 agonists (LABA), known as ICS/LABA, in the same fixed dose combination 
inhalers, depending on the inhaler device used: pressurized metered dose inhalers 
(pMDI) or dry powder inhalers (DPI), for the treatment of asthma in a real world back-
groung. Additionally asthma exacerbations, resources consumption, and associated 
costs were recorded. Methods: An observational, retrospective study was per-
formed. Patients aged ≥ 18 years, diagnosed with asthma, and who initiated an ICS/
LABA combination treatment during 2007-2011. Patients follow-up lasted for 3 years. 
Two treatment groups of patients were identified and assessed, depending on the 
inhaler device used: pMDI or DPI. The main measures were: adherence (posession 
drug ratio), persistence, asthma severity, ICS/LABA combinations used, exacerba-
tions, resources use and their costs (direct and indirect costs). Multivariate methods 
were used for the variables correction, with a p significance degree ‹0.05. Results: 
We included 2,082 asthma patients. Mean age 52.6 years, 65.3% female: 566 patients 
(27.2%) received an pMDI and 1,516 patients (72.8%) received an DPI. Patients who 
used and pMDI device showed a higher treatment adherence (RPM: 82.9% vs 80.8%, 
p< 0.05), fewer number of exacerbations (17.7% vs 24.9%, p< 0.001), and a lower health 
cost (€ 2,531 vs € 3,020, p< 0.001). ConClusions: Despite the limitations of the study, 
patients with asthma who started an ICS/LABA therapy who were treated with an 
pMDI device had higer adherence rates, better health outcomes and lower health 
costs for the Spanish National Health System.
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objeCtives: Long-term treatment adherence of patients with multiple sclerosis 
(MS) treated with injectable drugs is a general concern. Closely monitoring patients’ 
therapy adherence may be beneficial. The objective of this study was to assess treat-
ment adherence of MS patients treated with the injectable drug interferon beta-1a, 
administered with the RebiSmart system. Methods: A retrospective observational 
study was conducted, monitoring patients’ treatment adherence with the RebiSmart 
system in their normal treatment setting. The RebiSmart is an electronic, multidose 
auto-self-injection device aimed to improve assessment of treatment adherence. It 
contains a cartridge including a weekly dose. The device can accurately record time 
and dosage of each administered injection. Patients can view their own dosing log. 
Moreover, patients’ physicians can download the information providing an objective 
record of treatment adherence. To determine treatment adherence with RebiSmart, 
anonymous patient-level data of Dutch and German patients were extracted from 
the RebiSmart systems on dosing, time, and number of administrations over a five-
year time-period. Adherence was defined as taking > 80% of the treatment doses 
according to the schedule the doctor prescribed. Results: Data was collected from 
1832 patients (81% German, 73% females, average age 40.1 years). In total, 95% of 
the cartridges were used completely, indicating low drug spillage. Over the com-
plete observational period, 91% of all doses were administered according to doctor’s 
prescription. Examining individual adherence, 83% of the patients were considered 
adherent the whole period using interferon beta-1a. Results from Dutch and German 
patients were similar. ConClusions: Patients using the RebiSmart device in this 
study had a considerably higher adherence level than the approximately 60% adher-
ence indicated by previous research studying adherence of MS patients on disease-
modifying drugs. Drug spillage was low. Using an auto-injection device monitoring 
patients’ treatment behavior may positively contribute to treatment adherence. 
This should be further investigated in comparative research.
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objeCtives: To identify the impact of delivery device of inhaled corticosteroids and 
long-acting β 2-agonist (ICS/LABA) on asthma medication compliance, and inves-
tigate other factors associated with poor compliance. Methods: We conducted 
a retrospective and multicentre study based on a review of medical registries of 
asthmatic patients treated with ICS/LABA combinations (n= 2,213) whose medical 
devices were either dry powder inhalers (DPI) or pressurized metered-dose inhalers 
(pMDI). Medication compliance included persistence outcomes through 18 months 
and medication possession ratios. Data on potential confounders of treatment com-
pliance such as asthma exacerbations, comorbidities, demographic characteristics 
and healthcare resource utilization were also explored. Results: The probability of 
asthma medication compliance in case of DPI was lower compared to pMDI, which 
suggest that inhaler devices condition inhalation therapies. There were additional 
confounding factors that were considered as explanatory variables of compliance. 
A worse measure of airflow obstruction (FEV1), comorbidities and visiting the GP 
more than once per month decreased the probability of compliance. Within comor-
bidities, alcoholism was positively associated with compliance. Patients of 29-39, 
40-50 and 51-61 age groups or suffering from more than 2 exacerbations during the 
study period were more likely to comply with their medication regime. We identified 
differences among DPI devices and Accuhaler® device impacted negatively greater 
on compliance compared to other DPIs. We found that GP consultations reduced 
the probability of medication compliance for patients treated with Formoterol/
ogy laboratory standard working days. The time required to test one sample was 
timed for each methodology separately and the pertaining costs were calculated. 
The working dimension of the two technologies and of the instruments needed 
was also measured. Results: The hands-on time for SISH was 76.25% lower than 
the implementation of FISH and the dedicated spaces needed to carry out the SISH 
test was 45.27% less than FISH. Lastly, the costs of using an automated SISH system 
were lower than FISH. ConClusions: As a consequence of a significant reduc-
tion of laboratory personnel working hours, medical resources used and pathology 
laboratory spaces, the use of SISH technique to identify HER2 status is a cost-saving 
alternative to FISH from the perspective of the pathology laboratory.
MeDical Device/Diagnostics – Patient-Reported outcomes & Patient  
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objeCtives: Chronic Obstructive Pulmonary Disease (COPD) is a chronic respira-
tory disease with a high burden of disease and a relevant Public Health problem. 
The active patient active involvement is crucial to yield the proper disease con-
trol. The aim of the study was to assess treatment adherence with the combi-
nation of inhaled corticosteroids (ICS) and long-acting beta-2 agonists (LABA), 
known as ICS/LABA, in the same fixed dose combination inhalers, depending 
on the inhaler device used: pressurized metered dose inhalers (pMDI) or dry 
powder inhalers (DPI), for the treatment of COPD in a real world backgroung. 
Additionally COPD exacerbations, resources consumption, and associated costs 
were recorded. Methods: An observational, retrospective study was performed. 
Patients aged ≥ 40 years, diagnosed with COPD, and who initiated an ICS/LABA 
combination treatment during 2007-2011. Patients follow-up lasted for 3 years. 
Two treatment groups of patients were identified and assessed, depending on the 
inhaler device used: pMDI or DPI. The main measures were: adherence (posession 
drug ratio), persistence, asthma severity, ICS/LABA combinations used, exacer-
bations, resources use and their costs (direct and indirect costs). Multivariate 
methods were used for the variables correction, with a p significance degree 
‹0.05. Results: We included 1,418 COPD patients. Mean age 72.1 years, 82.7% male: 
594 patients (41.9%) received an pMDI and 824 patients (58.1%) received an DPI. 
Patients who used and pMDI device showed a higher treatment adherence (RPM: 
83.3% vs 79.9%, p< 0.05), fewer number of exacerbations (40.1% vs 48.2%, p= 0.002), 
and a lower health cost (€ 3,943 vs € 4,621, p< 0.001). ConClusions: Despite the 
limitations of the study, patients with COPD who started an ICS/LABA therapy 
who were treated with an pMDI device had higer adherence rates, better health 
outcomes and lower health costs for the Spanish National Health System.
PMD101
the iMPoRtance oF inhaleR Devices: an incoRRect inhaleR techniqUe 
leaDs to sUboPtiMal MeDication coMPliance in Patients With coPD
Darba J1, Ramírez G2, Sicras-Mainar A3, Francoli-Martínez P4, Torvinen S5, Sánchez-de la 
Rosa R6
1Universitat de Barcelona, Barcelona, Spain, 2BCN HEALTH ECONOMICS & OUTCOMES 
RESEARCH SL, Barcelona, Spain, 3Badalona Serveis Assistencials, Badalona. Barcelona, Spain, 
4Teva Pharma Spain, Alcobendas-Madrid, Spain, 5Teva Pharmaceuticals Europe B.V., Amsterdam, 
The Netherlands, 6Teva Pharmaceuticals, Madrid, Spain
objeCtives: This study aims to identify factors associated with poor compliance 
to COPD treatment in patients receiving a fixed-dose combination (FDC) of inhaled 
corticosteroids and long-acting β 2-agonist(ICS/LABA), focusing on the importance 
of inhaler devices. Methods: We conducted a retrospective and multicentre 
study based on a review of medical registries between 2007-2012 of COPD patients 
(n= 1,263) treated with ICS/LABA FDC, whose medical devices were either dry powder 
inhalers (DPI) or pressurized metered-dose inhalers (pMDI). Medication compli-
ance included persistence outcomes through 18 months and medication posses-
sion ratios. Data on exacerbations, comorbidities, demographic characteristics and 
healthcare resource utilization were also included as confounders of medication 
compliance. Results: The analyses revealed that COPD patients whose medication 
was delivered by a DPI were less likely to comply with their treatment compared 
to patients with pMDI, after adjusting for confounding factors, especially active 
ingredients. Younger groups of patients were less likely to comply with their medi-
cation compared to the oldest group. Smoker men were less likely to comply with 
their medication compared to women and non-smokers. Comorbidities decreased 
the probability of treatment compliance. Those patients that visited their GP once 
a month were more likely to comply with their medication regimen, however sub-
optimal compliance was more likely to occur among those patients who visited 
more than 3 times per month their GP. We also found that worsening of COPD is 
negatively associated with compliance. ConClusions: According to this study, 
inhaler devices influence patients’ compliance for long-term COPD medication. We 
also found that DPIs delivering ICS/LABA FDC had a negative impact on medica-
tion compliance. Patients’ clinic and socioeconomic characteristics were associated 
with compliance.
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